Audentes Therapeutics Inc (BOLD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Audentes Therapeutics Inc (BOLD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011912
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Audentes Therapeutics Inc (Audentes) is a biotechnology company that focuses on the development and commercialization of gene therapy products for serious and life-threatening rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment of Pompe disease; AT342, for the treatment of crigler-najjar syndrome; and AT307, for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia. Audentes offers viral vectors for gene therapy most frequently and track record off AAV in non-pathogenic product, among others. The company has collaboration with various patient, research and medical communities to advance its product candidates. Audentes is headquartered in San Francisco, California, the US.

Audentes Therapeutics Inc (BOLD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Partnerships 21
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Licensing Agreements 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 25
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Expands its Licensing Agreement with ReGenX Biosciences 28
Equity Offering 30
Audentes Therapeutics Files Registration Statement to Raise up to USD86.3 Million in Public Offering of Shares 30
Audentes Therapeutics Raises USD75 Million in IPO 31
Acquisition 32
Audentes Therapeutics Acquires Cardiogen Sciences 32
Audentes Therapeutics Inc – Key Competitors 33
Audentes Therapeutics Inc – Key Employees 34
Audentes Therapeutics Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 14, 2017: Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36
Aug 10, 2017: Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 38
May 11, 2017: Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 40
Mar 09, 2017: Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 42
Jan 09, 2017: Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance 45
Nov 10, 2016: Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update 48
Aug 31, 2016: Audentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update 49
Corporate Communications 51
Jun 13, 2017: Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors 51
May 08, 2017: Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer 52
Dec 13, 2016: Audentes Therapeutics Appoints Julie Anne Smith to Board of Directors 53
Jan 05, 2016: Audentes Therapeutics Appoints Scott W. Morrison to Board of Directors 54
Other Significant Developments 55
Nov 29, 2016: Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Audentes Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 25
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Expands its Licensing Agreement with ReGenX Biosciences 28
Audentes Therapeutics Files Registration Statement to Raise up to USD86.3 Million in Public Offering of Shares 30
Audentes Therapeutics Raises USD75 Million in IPO 31
Audentes Therapeutics Acquires Cardiogen Sciences 32
Audentes Therapeutics Inc, Key Competitors 33
Audentes Therapeutics Inc, Key Employees 34
Audentes Therapeutics Inc, Subsidiaries 35

★海外企業調査レポート[Audentes Therapeutics Inc (BOLD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sanderson Group plc (SND):企業の財務・戦略的SWOT分析
    Summary Sanderson Group plc (Sanderson) is a technology company that provides software solutions. The company’s products include Elucid, Swords, Unity, UnityF8 and Payroll Bureau. Sanderson offers services such as helpdesk and IT support, managed services, IT consultancy, project management, impleme …
  • Geberit Ag:企業の戦略・SWOT・財務分析
    Geberit Ag - Strategy, SWOT and Corporate Finance Report Summary Geberit Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • The Nisshin OilliO Group, Ltd.:企業の戦略・SWOT・財務情報
    The Nisshin OilliO Group, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Nisshin OilliO Group, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Terumo Corporation:企業のM&A・事業提携・投資動向
    Terumo Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Terumo Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Randstad Holding nv:企業の戦略・SWOT・財務情報
    Randstad Holding nv - Strategy, SWOT and Corporate Finance Report Summary Randstad Holding nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Boral Limited:企業の戦略・SWOT・財務情報
    Boral Limited - Strategy, SWOT and Corporate Finance Report Summary Boral Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Kimball Electronics, Inc. (KE):企業の財務・戦略的SWOT分析
    Kimball Electronics, Inc. (KE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Synergy
    Synergy - Strategy, SWOT and Corporate Finance Report Summary Synergy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Ricoh India Ltd:企業の戦略的SWOT分析
    Ricoh India Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • ITT Inc.:企業のM&A・事業提携・投資動向
    ITT Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ITT Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Westrock Company:企業の戦略・SWOT・財務情報
    Westrock Company - Strategy, SWOT and Corporate Finance Report Summary Westrock Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • The Bangchak Petroleum PCL (BCP):石油・ガス:M&Aディール及び事業提携情報
    Summary The Bangchak Petroleum PCL (Bangchak) is an oil and gas company. It carries out import of crude oil from both indigenous and overseas sources, and refines it into finished petroleum products. Its refinery produces gasoline, gasohol and diesel products. The company markets its petroleum produ …
  • Europ Assistance Holding SA:企業の戦略的SWOT分析
    Europ Assistance Holding SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Wausau Paper Corporation:企業の戦略・SWOT・財務情報
    Wausau Paper Corporation - Strategy, SWOT and Corporate Finance Report Summary Wausau Paper Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Evergreen Packaging Llc
    Evergreen Packaging Llc - Strategy, SWOT and Corporate Finance Report Summary Evergreen Packaging Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Zynex Inc (ZYXI):企業の財務・戦略的SWOT分析
    Summary Zynex Inc (Zynex) formerly Zynex Medical Inc operates as a medical technology company that designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. The company’s products include NexWave, a dual channel, multi-modality interferential curr …
  • PellePharm Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PellePharm Inc (PellePharm), a subsidiary of BridgeBio Inc, is a biotechnology company that develops and commercializes treatments for rare genetic dermatological conditions. The company’s lead clinical program, Patidegib, is a first-in-class topical gel formulation of a proprietary hedgehog …
  • Rafako SA (RFK):企業の財務・戦略的SWOT分析
    Rafako SA (RFK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Companhia Energetica de Minas Gerais – CEMIG:企業の戦略・SWOT・財務情報
    Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report Summary Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • StealthGas Inc (GASS):企業の財務・戦略的SWOT分析
    Summary StealthGas Inc (StealthGas) is an oil and gas shipping company that offers seaborne and oil and gas transportation services. The company provides transportation of petroleum and petrochemical gas products in liquefied forms. It transports byproducts of crude oil and natural gas including but …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆